Cargando…
The place of S-ketamine in fibromyalgia treatment (ESKEFIB): study protocol for a prospective, single-center, double-blind, randomized, parallel-group, dose-escalation controlled trial
BACKGROUND: Fibromyalgia is a chronic multidimensional pain disease with no curative treatment currently available. Its management relies on a multimodal approach involving pharmacologic and non-pharmacologic elements. Because a suggested factor in its etiology is a central sensitization phenomenon...
Autores principales: | Javorcikova, Zuzana, Dangoisse, Michel, Nikis, Stéphane, Lechat, Jean-Paul, Gillain, Aline, Fils, Jean-François, Van der Linden, Philippe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627027/ https://www.ncbi.nlm.nih.gov/pubmed/34838114 http://dx.doi.org/10.1186/s13063-021-05814-4 |
Ejemplares similares
-
Biomarkers in immunonutrition programme, is there still a need for new ones? A brief review
por: Forget, Patrice, et al.
Publicado: (2015) -
Systematic Review of the Use of Intravenous Ketamine for Fibromyalgia
por: Pastrak, Mila, et al.
Publicado: (2021) -
That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19
por: Davis, Matthew R., et al.
Publicado: (2020) -
Ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT): a multicentre, double-blind, randomised, parallel-group, superiority trial
por: Anderson, Ian M, et al.
Publicado: (2017) -
Outpatient Ketamine Infusions for the Treatment of Fibromyalgia and Chronic Pain Syndrome: A Case Report
por: Sharma, Sonakshi, et al.
Publicado: (2023)